Jefferies reiterated its Buy rating on AbbVie ABBV and raised the price target from $44.00 to $45.00.
Jefferies commented, "Humira growth guidance of "low double digit %" once again seems conservative against the product's recent momentum. We continue to expect near term performance to be driven by income funds, with the multiple then expected to expand significantly over the next 6-12 months once the pipeline visibility increases. We reiterate AbbVie as our top Global Pharma pick."
AbbVie closed at $36.69 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in